CCND1 Protein Overexpression
1 clinical trials · Condition
◉ Watch CCND1 Protein Overexpression
| Record | Firm | Date |
|---|---|---|
| Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT03946878) | M.D. Anderson Cancer Center | 2019-08-13 |
Track CCND1 Protein Overexpression automatically
Every clearance here is in the API, with alerts when new ones post.